Speclipse has unveiled its aesthetic and therapeutic medical device, 'PicoKEY', in Indonesia.


Speclipse Officially Launches 'PicoKEY' in Indonesia View original image

According to Speclipse on September 21, the company officially launched PicoKEY at the 25th anniversary event of the local distributor ‘Beauty World’ held in Jakarta, Indonesia.


Beauty World is a beauty distribution company with 25 years of experience in Indonesia and serves as the exclusive local partner for PicoKEY. The company handles a diverse portfolio, ranging from B2B medical devices to B2C products. With a dedicated sales force of over 200 employees, Beauty World operates its own distribution and sales network, making it one of the most influential distributors in the Indonesian market.


PicoKEY is an aesthetic and therapeutic medical device developed in-house by Speclipse, featuring a high-powered 300-picosecond laser. It is utilized for precision pigment lesion treatment and skin regeneration through precise and rapid energy delivery. Last month, Speclipse signed a distribution agreement with Beauty World for PicoKEY in Indonesia, and the company plans to further penetrate the local market through ongoing collaboration.


A representative from Beauty World stated, "We plan to establish PicoKEY as Indonesia's leading premium aesthetic medical device. Utilizing our distribution expertise gained from handling over 1,000 consumer goods and devices, as well as our sales and online marketing channels in the dermatology and beauty sector, we aim to increase recognition and expand sales of PicoKEY locally."



Hong Junghwan, CEO of Speclipse, said, "With this official launch, we will expand the sales base for PicoKEY in the Indonesian market. Building on our partnership with Beauty World, we will continue to enhance the competitiveness of our brand not only in Indonesia but also across the Southeast Asian market."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing